Topical tretinoin therapy and all-cause mortality

Martin A. Weinstock, Stephen F. Bingham, Robert A. Lew, Russell Hall, David Eilers, Robert Kirsner, Mark Naylor, James Kalivas, Gary Cole, Kimberly Marcolivio, Joseph Collins, John J. DiGiovanna, Julia E. Vertrees

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Objective: To evaluate the relation of topical tretinoin, a commonly used retinoid cream, with all-cause mortality in the Veterans Affairs Topical Tretinoin Chemoprevention Trial (VATTC). The planned outcome of this trial was risk of keratinocyte carcinoma, and systemic administration of certain retinoid compounds has been shown to reduce risk of this cancer but has also been associated with increased mortality risk among smokers. Design: The VATTC Trial was a blinded randomized chemoprevention trial, with 2- to 6-year follow-up. Oversight was provided by multiple independent committees. Setting: US Department of Veterans Affairs medical centers. Patients: A total of 1131 veterans were randomized. Their mean age was 71 years. Patients with a very high estimated short-term risk of death were excluded. Interventions: Application of tretinoin, 0.1%, or vehicle control cream twice daily to the face and ears. Main Outcome Measures: Death, which was not contemplated as an end point in the original study design. Results: The intervention was terminated 6 months early because of an excessive number of deaths in the tretinoin-treated group. Post hoc analysis of this difference revealed minor imbalances in age, comorbidity, and smoking status, all of which were important predictors of death. After adjusting for these imbalances, the difference in mortality between the randomized groups remained statistically significant. Conclusions: We observed an association of topical tretinoin therapy with death, but we do not infer a causal association that current evidence suggests is unlikely. Trial Registration: clinicaltrials.gov Identifier: NCT00007631.

Original languageEnglish
Pages (from-to)18-24
Number of pages7
JournalArchives of Dermatology
Volume145
Issue number1
DOIs
StatePublished - Jan 1 2009

Fingerprint

Tretinoin
Mortality
Chemoprevention
Veterans
Retinoids
Therapeutics
United States Department of Veterans Affairs
Keratinocytes
Ear
Comorbidity
Smoking
Outcome Assessment (Health Care)
Carcinoma
Neoplasms

ASJC Scopus subject areas

  • Dermatology

Cite this

Weinstock, M. A., Bingham, S. F., Lew, R. A., Hall, R., Eilers, D., Kirsner, R., ... Vertrees, J. E. (2009). Topical tretinoin therapy and all-cause mortality. Archives of Dermatology, 145(1), 18-24. https://doi.org/10.1001/archdermatol.2008.542

Topical tretinoin therapy and all-cause mortality. / Weinstock, Martin A.; Bingham, Stephen F.; Lew, Robert A.; Hall, Russell; Eilers, David; Kirsner, Robert; Naylor, Mark; Kalivas, James; Cole, Gary; Marcolivio, Kimberly; Collins, Joseph; DiGiovanna, John J.; Vertrees, Julia E.

In: Archives of Dermatology, Vol. 145, No. 1, 01.01.2009, p. 18-24.

Research output: Contribution to journalArticle

Weinstock, MA, Bingham, SF, Lew, RA, Hall, R, Eilers, D, Kirsner, R, Naylor, M, Kalivas, J, Cole, G, Marcolivio, K, Collins, J, DiGiovanna, JJ & Vertrees, JE 2009, 'Topical tretinoin therapy and all-cause mortality', Archives of Dermatology, vol. 145, no. 1, pp. 18-24. https://doi.org/10.1001/archdermatol.2008.542
Weinstock MA, Bingham SF, Lew RA, Hall R, Eilers D, Kirsner R et al. Topical tretinoin therapy and all-cause mortality. Archives of Dermatology. 2009 Jan 1;145(1):18-24. https://doi.org/10.1001/archdermatol.2008.542
Weinstock, Martin A. ; Bingham, Stephen F. ; Lew, Robert A. ; Hall, Russell ; Eilers, David ; Kirsner, Robert ; Naylor, Mark ; Kalivas, James ; Cole, Gary ; Marcolivio, Kimberly ; Collins, Joseph ; DiGiovanna, John J. ; Vertrees, Julia E. / Topical tretinoin therapy and all-cause mortality. In: Archives of Dermatology. 2009 ; Vol. 145, No. 1. pp. 18-24.
@article{693f300e830e4a14863824634f0ecf84,
title = "Topical tretinoin therapy and all-cause mortality",
abstract = "Objective: To evaluate the relation of topical tretinoin, a commonly used retinoid cream, with all-cause mortality in the Veterans Affairs Topical Tretinoin Chemoprevention Trial (VATTC). The planned outcome of this trial was risk of keratinocyte carcinoma, and systemic administration of certain retinoid compounds has been shown to reduce risk of this cancer but has also been associated with increased mortality risk among smokers. Design: The VATTC Trial was a blinded randomized chemoprevention trial, with 2- to 6-year follow-up. Oversight was provided by multiple independent committees. Setting: US Department of Veterans Affairs medical centers. Patients: A total of 1131 veterans were randomized. Their mean age was 71 years. Patients with a very high estimated short-term risk of death were excluded. Interventions: Application of tretinoin, 0.1{\%}, or vehicle control cream twice daily to the face and ears. Main Outcome Measures: Death, which was not contemplated as an end point in the original study design. Results: The intervention was terminated 6 months early because of an excessive number of deaths in the tretinoin-treated group. Post hoc analysis of this difference revealed minor imbalances in age, comorbidity, and smoking status, all of which were important predictors of death. After adjusting for these imbalances, the difference in mortality between the randomized groups remained statistically significant. Conclusions: We observed an association of topical tretinoin therapy with death, but we do not infer a causal association that current evidence suggests is unlikely. Trial Registration: clinicaltrials.gov Identifier: NCT00007631.",
author = "Weinstock, {Martin A.} and Bingham, {Stephen F.} and Lew, {Robert A.} and Russell Hall and David Eilers and Robert Kirsner and Mark Naylor and James Kalivas and Gary Cole and Kimberly Marcolivio and Joseph Collins and DiGiovanna, {John J.} and Vertrees, {Julia E.}",
year = "2009",
month = "1",
day = "1",
doi = "10.1001/archdermatol.2008.542",
language = "English",
volume = "145",
pages = "18--24",
journal = "JAMA Dermatology",
issn = "2168-6068",
publisher = "American Medical Association",
number = "1",

}

TY - JOUR

T1 - Topical tretinoin therapy and all-cause mortality

AU - Weinstock, Martin A.

AU - Bingham, Stephen F.

AU - Lew, Robert A.

AU - Hall, Russell

AU - Eilers, David

AU - Kirsner, Robert

AU - Naylor, Mark

AU - Kalivas, James

AU - Cole, Gary

AU - Marcolivio, Kimberly

AU - Collins, Joseph

AU - DiGiovanna, John J.

AU - Vertrees, Julia E.

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Objective: To evaluate the relation of topical tretinoin, a commonly used retinoid cream, with all-cause mortality in the Veterans Affairs Topical Tretinoin Chemoprevention Trial (VATTC). The planned outcome of this trial was risk of keratinocyte carcinoma, and systemic administration of certain retinoid compounds has been shown to reduce risk of this cancer but has also been associated with increased mortality risk among smokers. Design: The VATTC Trial was a blinded randomized chemoprevention trial, with 2- to 6-year follow-up. Oversight was provided by multiple independent committees. Setting: US Department of Veterans Affairs medical centers. Patients: A total of 1131 veterans were randomized. Their mean age was 71 years. Patients with a very high estimated short-term risk of death were excluded. Interventions: Application of tretinoin, 0.1%, or vehicle control cream twice daily to the face and ears. Main Outcome Measures: Death, which was not contemplated as an end point in the original study design. Results: The intervention was terminated 6 months early because of an excessive number of deaths in the tretinoin-treated group. Post hoc analysis of this difference revealed minor imbalances in age, comorbidity, and smoking status, all of which were important predictors of death. After adjusting for these imbalances, the difference in mortality between the randomized groups remained statistically significant. Conclusions: We observed an association of topical tretinoin therapy with death, but we do not infer a causal association that current evidence suggests is unlikely. Trial Registration: clinicaltrials.gov Identifier: NCT00007631.

AB - Objective: To evaluate the relation of topical tretinoin, a commonly used retinoid cream, with all-cause mortality in the Veterans Affairs Topical Tretinoin Chemoprevention Trial (VATTC). The planned outcome of this trial was risk of keratinocyte carcinoma, and systemic administration of certain retinoid compounds has been shown to reduce risk of this cancer but has also been associated with increased mortality risk among smokers. Design: The VATTC Trial was a blinded randomized chemoprevention trial, with 2- to 6-year follow-up. Oversight was provided by multiple independent committees. Setting: US Department of Veterans Affairs medical centers. Patients: A total of 1131 veterans were randomized. Their mean age was 71 years. Patients with a very high estimated short-term risk of death were excluded. Interventions: Application of tretinoin, 0.1%, or vehicle control cream twice daily to the face and ears. Main Outcome Measures: Death, which was not contemplated as an end point in the original study design. Results: The intervention was terminated 6 months early because of an excessive number of deaths in the tretinoin-treated group. Post hoc analysis of this difference revealed minor imbalances in age, comorbidity, and smoking status, all of which were important predictors of death. After adjusting for these imbalances, the difference in mortality between the randomized groups remained statistically significant. Conclusions: We observed an association of topical tretinoin therapy with death, but we do not infer a causal association that current evidence suggests is unlikely. Trial Registration: clinicaltrials.gov Identifier: NCT00007631.

UR - http://www.scopus.com/inward/record.url?scp=58849132286&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58849132286&partnerID=8YFLogxK

U2 - 10.1001/archdermatol.2008.542

DO - 10.1001/archdermatol.2008.542

M3 - Article

C2 - 19153339

AN - SCOPUS:58849132286

VL - 145

SP - 18

EP - 24

JO - JAMA Dermatology

JF - JAMA Dermatology

SN - 2168-6068

IS - 1

ER -